
Opinion|Videos|May 8, 2024
Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Integrating Combination Therapies for Type 2 Diabetes and CKD
2
Building a Unified Approach to Cardio Kidney Metabolic Health
3
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
4
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
5














































































































































































































